Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension

Title:

Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension

Creator:

Fedor Šimko, Jana Matúšková, Ivan Ľupták, Terézia Pinčíková, Kristína Krajčírovičová, Svetoslav Štvrtina, Pomšár, J., Václav Pelouch, Ľudovít Paulis, and Oľga Pecháňová

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:ae175403-470c-44de-92a0-9fd446e72114
uuid:ae175403-470c-44de-92a0-9fd446e72114
issn:0862-8408

Subject:

Fyziologie člověka a srovnávací fyziologie, hypertenze, oxid dusnatý, hypertension, nitric oxide, L-NAME, NO-deficient hypertension, spironolactone, left ventricular hypertrophy, aorta remodeling, 14, and 612

Type:

article, články, model:article, and TEXT

Format:

print, bez média, and svazek

Description:

Aldosterone receptor antagonist, spironolactone, has been shown to prevent remodeling of the heart in several models of left ventricular hypertrophy. The aim of the present study was to determine whether the treatment with spironolactone can prevent hypertension, reduction of tissue nitric oxide synthase activity and left ventricular (LV) and aortic remodeling in NG-nitro-L-arginine methyl ester (L-NAME)-induced hypertension. Four groups of rats were investigated: control, spironolactone (200 mg/kg), L-NAME (40 mg/kg) and L-NAME + spironolactone (in corresponding dosage). Animals were studied after 5 weeks of treatment. The decrease of NO-synthase activity in the LV and kidney was associated with the development of hypertension and LV hypertrophy, with increased DNA concentration in the LV, and remodeling of the aorta in the L-NAME group. Spironolactone prevented the inhibition of NO-synthase activity in the LV and kidney and partially attenuated hypertension and LVH development and the increase in DNA concentration. However, remodeling of the aorta was not prevented by spironolactone treatment. We conclude that the aldosterone receptor antagonist spironolactone improved nitric oxide production and partially prevented hypertension and LVH development without preventing hypertrophy of the aorta in NO-deficient hypertension. The reactive growth of the heart and aorta seems to be controlled by different mechanisms in L-NAMEinduced hypertension., F. Šimko, J. Matúšková, I. L'upták, T. Pinčíková, K. Krajčírovičová, S. Štvrtina, J. Pomšár, V. Pelouch, L'. Paulis, O. Pecháňová., and Obsahuje bibliografii

Language:

English

Rights:

http://creativecommons.org/licenses/by-nc-sa/4.0/
policy:public

Source:

Physiological research | 2007 Volume:56 | Number:Suppl 2

Harvested from:

CDK

Metadata only:

false